GABA (Gamma Amino Butyric Acid) Medication for Tobacco
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to examine the effects of a GABA (gamma amino butyric
acid)-enhancing medication, pregabalin (300 mg/day), on smoking behavior, tobacco withdrawal
and cigarette craving in smokers. We hypothesize that in smokers, pregabalin at 300 mg/day,
will be more effective than placebo in decreasing smoking behavior and attenuating tobacco
withdrawal and cigarette craving.
Phase:
Early Phase 1
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute on Drug Abuse (NIDA) US Department of Veterans Affairs VA Office of Research and Development